ReviewDrug design, development and therapy2026
Progress in the Application of Esketamine During the Perioperative Period.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Clinical research progress of esketamine in perioperative neuroprotection: from mechanisms to therapeutic neuroprotection.Frontiers in pharmacology · 2026Review
- Effects of Intravenous Esketamine or Magnesium Sulfate on Early Postoperative Negative Emotions and Pain in Patients Undergoing Endoscopic Sinus Surgery: A Randomized Controlled Trial.Therapeutics and clinical risk management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esketamine is the S-enantiomer of ketamine. As a potent NMDA receptor antagonist with high affinity, it exhibits sedative, analgesic, and antidepressant properties, among others. Compared with racemic ketamine, esketamine demonstrates approximately twice the potency, along with several advantages: a rapid onset of action, mild respiratory depression, and fewer adverse psychiatric effects. In recent years, the perioperative application of esketamine has garnered increasing attention. It has demonstrated potential application value in clinical practice, particularly in obstetric anesthesia, pediatric surgical anesthesia, orthopedic surgical anesthesia, painless diagnostic and therapeutic procedures, and special clinical scenarios. The pharmacological mechanism of esketamine has not been fully elucidated to date, and research on its perioperative application remains relatively limited. High quality evidence from large-sample, multicenter studies is scarce, and no unified standard has been established for its administration regimens and dosages. Nonetheless, this paper provides a summary of the pharmacological properties, potential mechanisms of action, and current clinical applications of esketamine across diverse clinical scenarios, with the overarching goal of providing evidence to support its rational use in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.